Company* (Country; Symbol)

Funding Institution

Amount (M)

Type

Details (Date)


Acambis plc (UK; ACAM)

Centers for Disease Control and Prevention

$30

Contract award

Acambis will supply a further 10M doses of ACAM2000 smallpox vaccine, for $30M; Acambis previously supplied 182.5M doses (9/13)

Achaogen Inc.*

U.S. Department of Defense

$24.7

Defense Threat Reduction Agency contract

DTRA funded the first year of a potential $24.7M four-year deal under which Achaogen will develop small-molecule therapies to treat anthrax and other biothreat agents (10/24)

Adnexus Therapeutics Inc.*

National Institute of Arthritis and Musculoskeletal and Skin Diseases

ND

Phase I SBIR grant

Funds will support development of Adnectin products, which are human fibronectin (9/5)

Alnylam Pharmaceuticals Inc. (ALNY)

U.S. Department of Defense

$1.1

Defense appropriation

Funds will support development of RNAi therapeutics to combat natural or man-made biological threats (10/4)

Alnylam Pharmaceuticals Inc. (ALNY)

National Institute of Allergy and Infectious Diseases

$23

Contract

The four-year award will support development of RNAi therapeutics as antiviral drugs targeting the Ebola virus (9/28)

Alnylam Pharmaceuticals Inc. (ALNY)

National Institute of Allergy and Infectious Diseases

$0.59

SBIR grant

The one-year grant will support development of RNAi therapeutics as antivirals against multiple influenza strains, including the H5N1 virus (9/6)

Alteon Inc. (AMEX:ALT)

Juvenile Diabetes Research Foundation

ND

Grant

Funds will support Phase II trials being run by an Alteon collaborator in Australia, which will test the use of alagebrium on renal function in patients with Type I diabetes and microalbuminuria (7/10)

Althea Technologies Inc.*

National Institute of Allergy and Infectious Diseases

$0.91

Subcontract from Advanced BioScience Laboratories Inc.

Althea got a manufacturing contract to produce a DNA-based HIV-1 vaccine (8/29)

Altor BioScience Corp.*

National Cancer Institute

$1.2

Phase II SBIR grant

The two-year grant will support further development of processes for making therapeutic antibodies in transgenic lettuce (7/25)

Arbor Vita Corp.*

National Institutes of Health

$0.9

Phase II SBIR grant

The two-year grant will fund work on an in vitro diagnostic test for cervical precancer and cancer, which is based on detection of the HPV-E6 oncoprotein (9/20)

Avanir Pharmaceuticals Inc. (AVNR)

National Institute of Allergy and Infectious Diseases

$2

Cooperative Research Partnerships for Biodefense grant

Funding will support establishment of a cGMP manufacturing process and to test efficacy of the fully human monoclonal antibody AVP-21D9 against inhalation anthrax in non-human primates (6/30)

Avant Immunotherapeutics Inc. (AVAN)

U.S. Department of Defense

$2.6

Defense appropriation

Funds will support continued development of an oral combination vaccine to protect against anthrax and plague (10/2)

Avant Immunotherapeutics Inc. (AVAN)

National Institute of Allergy and Infectious Diseases

$0.75

Phase II SBIR grant

Funds will support further development and manufacture of Ty800, the company's single-dose, oral typhoid vaccine (9/27)

Avant Immunotherapeutics Inc. (AVAN)

Bill and Melinda Gates Foundation

$21

Funding support

The International Vaccine Institute received the funding to conduct further clinical trials of Avant's CholeraGarde cholera vaccine in Bangladesh and India (8/2)

Axordia Ltd.* (UK) and Stem Cell Sciences Ltd. (UK; AIM:STEM)

European Commission

ND

ESTOOLS program funding

The companies are among those participating in the €12M ESTOOLS program focused on advancing the science surrounding human embryonic stem cells (8/28)

BioForce Nanosciences Holdings Inc. (OTC BB:BFNH)

National Human Genome Research Institute

$0.4

Funding award

Funding will support development of the company's surface patterning tools; an additional $0.4M award is possible (9/26)

Bionovo Inc. (OTC BB:BNVI)

National Institutes of Health

$1

RO1 grant

Funds will support research on a novel mechanism of nuclear transport regulation in cancer cells (7/12)

Biota Holdings Ltd. (Australia; ASX:BTA)

National Institute of Allergy and Infectious Diseases

$2.4

Contract award

Biota got $2.4M of a potential $8.5M over four years for development of a long-acting class of neuraminidase inhibitors, named FluNet (8/8)

Biothera*

National Institutes of Health

$3.6

SBIR Advanced Technology Grant

Biothera got funding for Phase I of a five-year $3.6M program to develop its Imprime WGP drug to treat bone marrow injury from acute radiation exposure (9/5)

Brain AG* (Germany)

German government

ND

BioChance Plus research grant

The company and university groups will develop high-throughput systems in the area of industrially relevant biocatalysts (7/26)

Cangene Corp. (Canada; TSX:CNJ)

U.S. Department of Health and Human Services

$143

Project BioShield contract

Cangene will provide 10,000 doses of anthrax immune globulin over three years under a modification to a September 2005 contract (7/28)

Celera Genomics (NYSE:CRA)

National Institutes of Health

$0.9

Grant

Funds will support development of an in vitro diagnostic test for the H5N1 influenza virus (8/21)

Cepheid Inc. (CPHD)

National Institute of Allergy and Infectious Diseases

ND

Phase II STTR grant

Cepheid and the University of Medicine and Dentistry of New Jersey will use the funds in development of a PCR-based test for tuberculosis (8/30)

ChemDiv Inc.* and Yale University

National Institutes of Health

ND

Phase II grant

ChemDiv and Yale University were awarded the funding to further develop small-molecule inhibitors of the melanocortin-2 receptor GPCR (8/30)

Cleveland BioLabs Inc. (CBLI)

National Cancer Institute

$0.75

Phase II SBIR contract

Funds will support development of small-molecule radioprotectors, to reduce cell damage from radiation exposure (9/6)

CombiMatrix Group (CBMX)

U.S. Department of Defense

$2

Defense appropriations

Two allocations of $1M each will support continued development of microarray technologies for detecting biological-threat agents and infectious pathogens, such as the H5N1 influenza virus (10/9)

Crucell NV (the Netherlands; CRXL)

National Institute of Allergy and Infectious Diseases

$16.2

Contract award

Funding supports work with Beth Israel Deaconess Medical Center and Charles River Laboratories Inc. on development of an HIV vaccine that uses live vectors (10/9)

Cyto Pulse Sciences Inc.*

National Institute of Allergy and Infectious Diseases

$2

Phase II grant

The two-year award will fund development of the company's Easy Vax DNA vaccine delivery system, for use against biodefense pathogens (8/16)

CytRx Corp. (CYTR)

National Institute of Diabetes and Digestive and Kidney Diseases

$0.22

SBIR grant

Funds will support development of inhibitors to fatty acid synthase for the treatment of Type II diabetes and obesity (9/27)

Develogen AG* (Germany)

Ministry of Industry, Trade and Labor (Israel)

€0.475 ($0.6)

Grant

The grant continues support being provided to DeveloGen's subsidiary in Israel for the DiaPep277 program for treating autoimmune diabetes (7/4)

DOR BioPharma Inc. (OTC BB:DORB)

National Institute of Allergy and Infectious Diseases

$4.8

Grant

Funds will support continued development of RiVax, a recombinant vaccine against ricin toxin (9/29)

DOR BioPharma Inc. (OTC BB:DORB)

National Institute of Allergy and Infectious Diseases

$0.5

Phase I SBIR grant

Funds will support research on BT-VACC, a multivalent mucosal vaccine against botulinum toxin (9/29)

Emergent BioSolutions Inc.*

National Institute of Allergy and Infectious Diseases

$3.8

Grants

Two grants totaling $3.8M will support development of the company's anthrax immune globulin therapeutic (8/31)

Epeius Biotechnologies Corp.*

U.S. FDA

ND

Grant

Funds will support research on pharmacology and toxicology of the gene therapy agent Rexin-G in patients with advanced pancreatic cancer (10/2)

Evogenix Ltd. (Australia; ASX:EGX)

Australian government

A$1.66 ($1.2)

Commercial Ready grant

The two-year grant will support development of DMF10, an anticancer hamster antibody (7/5)

FibroGen Inc.*

National Heart, Lung and Blood Institute

ND

Phase II SBIR grant

Funds will support development of hypoxia-inducible factor prolyl hydroxylase inhibitors for treating sickle cell disease (8/22)

Galapagos NV (Belgium; Euronext:GLPG)

Flanders government (Belgium)

€1.8 ($2.3)

Grant

Funds will support development of biological models for treating rheumatoid arthritis and osteoporosis; Galapagos will work with three Belgian institutions on the programs (7/26)

GeneGo Inc.*

National Cancer Institute

ND

Phase II SBIR grant

Funds will support work with the Mayo Clinic on discovery of biomarkers implicated in breast cancer (10/3)

GeneGo Inc.*

U.S. Department of Defense

$0.75

Phase II SBIR grant

Funds will support development of a systems biology suite for functional analysis of proteomics data (8/8)

Genomatix Software GmbH* (Germany)

Federal Ministry of Education and Research (Germany)

$1.6

BioChance research contract

The company and two academic partners got two years of fundings for research in RNAi-mediated regulatory networks (9/14)

GenVec Inc. (GNVC)

National Institute of Allergy and Infectious Diseases

$3.56

Subcontract award from SAIC-Frederick Inc.

Additional funds under the deal with the NIAID's Vaccine Research Center will support development of adenovector-based HIV vaccines (10/10)

GenVec Inc. (GNVC)

National Institute of Allergy and Infectious Diseases

$0.43

Phase I SBIR grant

The Biodefense Program funds will support development of an adenovector-based vaccine technology (8/29)

GTC Biotherapeutics Inc. (GTCB)

National Institutes of Health

$1.4

SBIR grant

GTC got additional funds for its CD137 monoclonal antibody program, which targets solid tumors and autoimmune diseases (10/5)

Helicos BioSciences Corp.*

National Human Genome Research Institute

$2

Grant

Funds will support fund research of a single-molecule sequencing technology for low-cost resequencing applications and de novo sequencing of large genomes (10/4)

Immatics Biotechnologies GmbH* (Germany)

Federal Ministry of Education and Research (Germany)

€0.57 ($0.71)

Grants

Grants will support preclinical development of a therapeutic vaccine for pancreatic cancer, and development of a process for isolating tumor-specific T cells from cancer patients (9/6)

Immunotope Inc.*

U.S. Army

$0.78

Phase II SBIR grant

Funds will be used in development of an autoantibody-based, early stage diagnostic test for prostate cancer (10/23)

Inovio Biomedical Corp. (AMEX:INO)

U.S. Department of Defense

$1.1

Defense appropriation

For development of its electroporation-based gene delivery technology for vaccination against infectious diseases, including bioterrorism agents (10/19)

Invitrogen Corp. (IVGN)

U.S. Department of Defense

$1.24

Contract award

Funding is an extension to existing contract to support research on protein microarray technology to detect and analyze biothreat agents (9/12)

Javelin Pharmaceuticals Inc. (AMEX:JAV)

National Cancer Institute

$0.75

Phase II SBIR grant

Funds will support clinical development of PMI-150 (intranasal ketamine) for treating pain (7/7)

Juvaris BioTherapeutics Inc.*

National Cancer Institute

ND

Phase I SBIR grant

One-year grant will support work with Penn State College of Medicine on a therapeutic vaccine approach for treating acute myelogenous leukemia (9/26)

Juvaris BioTherapeutics Inc.*

National Institute of Allergy and Infectious Diseases

$1

Phase I SBIR grant

One-year grant will support work with Colorado State University to develop approach for treating F. tularensis (tularemia), a priority pathogen (9/13)

Lentigen Corp.*

National Institutes of Health

ND

Phase I SBIR grant

For evaluation of using lentiviral-engineered T cells that express chimeric receptors and signaling modules to improve efficacy of cancer therapies directed against the tumor-associated antigen mesothelin (10/17)

Lexicon Genetics Inc. (LEXG)

U.S. Defense Advanced Research Projects Agency

ND

Funding award

Lexicon will work to identify targets for drug discovery efforts in the area of sleep deprivation, under a one-year contract (9/26)

LigoCyte Pharmaceuticals Inc.*

U.S. Department of Defense

$2.3

Contract award

Funding will support continued validation of a third-generation mucosal anthrax vaccine (7/6)

MacroGenics Inc.*

National Institute of Allergy and Infectious Diseases

$50

Contract award

The five-year award will support development of a preclinical monoclonal antibody to West Nile virus through Phase II trials (10/3)

MacroGenics Inc.*

National Institute of Allergy and Infectious Diseases

$6.8

Grant

Funds of up to $6.8M will be used to support development of a monoclonal antibody against smallpox virus, in collaboration with the NIAID (10/3)

MacroGenics Inc.*

National Institute of Allergy and Infectious Diseases

$6

Subcontract from St. Jude Children's Research Hospital

Up to $6M will be awarded for development of cross-neutralizing monoclonal antibodies specific for the H5N1 influenza virus (10/3)

MaxThera Inc.*

National Institute of Allergy and Infectious Diseases

$0.76

Phase I SBIR grant

The two-year grant will support efforts to design and develop antibiotics against potential lethal infections complicated by antibiotic resistance (9/22)

Nastech Pharmaceutical Co. Inc. (NSTK)

National Institute of Allergy and Infectious Diseases

ND

Phase I SBIR grant

Funds will be used for further development of small-interfering RNA therapeutics to prevent and treat influenza (9/29)

Omicia Inc.*

National Human Genome Research Institute

$0.79

Phase II SBIR grant

Funds will be used to refine the disease marker genome annotation system prototyped by the company during Phase I of the grant (9/13)

PharmAthene Inc.*

National Institutes of Health

$1.7

Countermeasures Against Chemical Threats grant

Funds will support continued development of the broad-spectrum chemical nerve agent therapy, Protexia, a recombinant form of human butyrylcholinesterase (10/18)

PharmAthene Inc.* and Medarex Inc. (MEDX)

U.S. Department of Defense

$1

Defense appropriation

Funds will support ongoing development of Valortim, a fully human monoclonal antibody being developed for anthrax infection (10/11)

PharmAthene Inc.*

Department of Defense, U.S Army Space and Missile Command

$34.7

Contract

Multiyear contract worth up to $213M is for development of the broad-spectrum chemical nerve agent prophylaxis, Protexia; $34.7M already was allocated (9/25)

Pluristem Life Systems Inc. (Israel; OTC BB:PLRS)

Ministry of Trade and Industry (Israel)

$0.47

Grant

The royalty-bearing grant will support development of Pluristem's stem cell product PLX-I, which may have use in bone marrow transplants (8/24)

Pressure BioSciences Inc. (PBIO)

National Institutes of Health

$0.149

Phase I SBIR grant

Grant will help fund experiments on a pressure cycling technology for use in extracting protein biomarkers, subcellular molecular complexes and organelles from cells and tissues (10/4)

ProlX Pharmaceuticals Corp.*

National Institutes of Health

$4.5

Phase II SBIR grants

Two grants totaling about $4.5M were awarded for clinical and preclinical development of the cancer drugs PX-12 and PX-866, respectively (7/31)

ProNAi Therapeutics Inc.*

Michigan Economic Development Corp.

$3.3

21st Century Jobs Fund award

Funding will support development of nucleic-acid drugs based on DNA interference (9/12)

Protiva Biotherapeutics Inc.* (Canada)

U.S. Defense Threat Reduction Agency

$1.4

Grant

Protiva is part of a consortium that together is getting $3.6M to develop a therapy for hemorrhagic fever viral infection; it includes the U.S. Army Medical Research Institute of Infectious Diseases (9/19)

PTC Therapeutics Inc.*

Office of Orphan Products Development of the FDA

ND

Grant

Funds will support patient-related costs of ongoing Phase II trial of PTC124 for treating nonsense-mutation-mediated Duchenne muscular dystrophy (10/19)

PTC Therapeutics Inc.*

U.S. Defense Threat Reduction Agency

$17.2

Funding award

Funds will go toward discovery and development of broad-spectrum small-molecule antibacterials against biowarfare or bioterrorism agents (10/2)

PTC Therapeutics Inc.*

U.S. Department of Defense

$2.2

Grant

The three-year grant will be used on development of PTC299 as a treatment for breast cancer (9/26)

QBI Life Sciences (division of Quintessence Biosciences Inc.)

National Institutes of Health

ND

Phase I grant

QBI will work with GWC Technologies to develop an assay that provides absorption profiles for early stage drug candidates (7/14)

Regeneron Pharmaceuticals Inc. (REGN)

National Institutes of Health

ND

Grant

Regeneron will use its VelociGene technology to target 3,500 genes under a five-year grant related to the NIH's Knockout Mouse Project (9/7)

RegeneRx Bio-pharmaceuticals Inc. (AMEX:RGN)

FDA's Office of Orphan Products Development

$0.545

Grant

Fund will support clinical development of its drug candidate based on thymosin beta 4 for treating the rare genetic disease epidermolysis bullosa (8/9)

Rx3 Pharmaceuticals Inc.*

National Institutes of Health

$1.5

Grants

Two grants totaling $1.5M will help fund work in the area of antibiotic development (9/25)

SIGA Technologies Inc. (SIGA)

National Institute of Allergy and Infectious Diseases

$16.5

Contract award

Three-year funding will support development of its smallpox drug candidate SIGA-246 (10/4)

SIGA Technologies Inc. (SIGA)

National Institutes of Health

$6

Grant

Funding will support development of antiviral drugs for Lassa fever virus (9/12)

SIGA Technologies Inc.(SIGA)

National Institutes of Health

$4.8

Phase II SBIR grant

Funding will support clinical development of its smallpox drug candidate SIGA-246 (8/2)

Syntaxin Ltd.* (UK)

UK Department for Trade and Industry

£1.2 ($2.2)

Collaborative R&D grant

Syntaxin, University College London and the UK Health Protection Agency will work to develop enhanced methods for bioprocessing complex proteins, for use as drugs (7/6)

Tissue Genesis Inc.*

U.S. Department of Defense

$4.5

Contract award

Funding will support continued research and development on cell recovery and cell delivery systems (9/18)

VASTox plc (UK; AIM:VOX)

UK Department of Trade and Industry

£0.37 ($0.69)

Matching grant

Funding, including academic collaboratories, totaled £0.91M, for a research program in stem cells (9/20)

Velcura Therapeutics Inc.*

National Institute on Aging

$0.274

Phase I SBIR grant

Funds will be used to further identify the genes and/or protein networks modulated during human bone formation (8/30)

Xechem International Inc. (OTC BB:XKEM)

National Heart, Lung and Blood Institute

$0.473

SBIR grant

Funds will support toxicity studies on 5-HMF, a five-membered heterocyclic anti-sickling compound (10/4)

XOMA Ltd. (XOMA)

National Institute of Allergy and Infectious Diseases

$16 award

Contract

Funding will support pre-Phase I development of monoclonal antibodies for treating botulism resulting from bioterrorism (7/31)


Notes:

* Indicates a privately held company.

Currency conversions reflect values at the time of a deal's announcement.

SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer.

Unless otherwise indicated, symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.

No Comments